Whether it´s oncolytic viruses or vectors for cancer therapy or modern vaccines, the demand for development, production or filling capacities is rising rapidly. To keep pace with this rise in customer demand, Vibalogics, which recently became part of the Recipharm Group, is investing around US$50m in the expansion of its Cuxhaven site by the end of the year, and even more in the US site near Boston.
Knowledge-based contract services
BackgroundTo install a newly created Chief Scientific Officer position and to hire a biotech veteran is a signal sent by Rentschler Biopharma, celebrating 150 years.
Clinical Microbiomics A/S bags €10m financing
Latest NewsDanish microbiome specialist Clinical Microbiomics A/S has completed a €10m growth financing led by – Seventure Partners.
EU starts largest study on factors affecting mental health
Latest NewsThe EU Commission has granted £8.4m for Youth-GEMS, the largest ever study to identify genetic and other risks affecting mental health in adolescence.
Standing Ovation wins Industria Biotec’s start-up pitch
Latest NewsFrench Standing Ovation has won the start-up pitch of Industria Biotec, held for the first time in Berlin. The event presents biotechnological solutions to save the climate.
Screening Platform
ProductsSingle B cell screening is a powerful and efficient strategy for generating antigen-specific monoclonal antibodies (mAbs).
A spotlight on tomorrow’s CRO
Sponsored PublicationsThe CRO industry is predicted to grow considerably over the next five years. Trials are becoming more complex, and technology is becoming increasingly interwoven with processes. The CRO of tomorrow must be tech smart, agile, and environmentally conscious to remain relevant. In this changing landscape, how does a CRO cut through the noise in 2022-30?
MaaT Pharma appointed new CSO
AppointmentsFrench MaaT Pharma has appointed Nathalie Corvaïa as Chief Scientific Officer and will strengthens its R&D Activities in Immuno-Oncology.
Araris Biotech closes $24m Series A financing round
Latest NewsSwiss ADC maker Araris Biotech AG has added a $24m financing round to its CHF15.2m (S17.8m) seed round in 2020 to expand its portfolio of proprietary antibody drug conjugates.
New Protein Fund I supports 17 alternative protein start-ups
Latest NewsWith money from its $50m New Protein Fund, Big Idea Ventures funds in 17 pre-seed plant-based, cell-based and microbial food, ingredient and technology companies.
Bringing virotherapy forward
BackgroundWhether it´s oncolytic viruses or vectors for cancer therapy or modern vaccines, the demand for development, production or filling capacities is rising rapidly. To keep pace with this rise in customer demand, Vibalogics, which recently became part of the Recipharm Group, is investing around US$50m in the expansion of its Cuxhaven site by the end of the year, and even more in the US site near Boston.